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Background: Pacific Biosciences technology provides a fundamentally new data type that provides the potential to
overcome some limitations of current next generation sequencing platforms by providing significantly longer reads,
single molecule sequencing, low composition bias and an error profile that is orthogonal to other platforms. With
these potential advantages in mind, we here evaluate the utility of the Pacific Biosciences RS platform for human
medical amplicon resequencing projects.
Results: We evaluated the Pacific Biosciences technology for SNP discovery in medical resequencing projects using
the Genome Analysis Toolkit, observing high sensitivity and specificity for calling differences in amplicons
containing known true or false SNPs. We assessed data quality: most errors were indels (~14%) with few apparent
miscalls (~1%). In this work, we define a custom data processing pipeline for Pacific Biosciences data for human
data analysis.
Conclusion: Critically, the error properties were largely free of the context-specific effects that affect other
sequencing technologies. These data show excellent utility for follow-up validation and extension studies in human
data and medical genetics projects, but can be extended to other organisms with a reference genome.Background
Massively parallel DNA sequencing technologies power
many of today’s studies of genetic traits, including popu-
lation diversity projects like the 1000 Genomes (1000 G)
[1], the sequencing-based successors to disease associ-
ation studies [2-5], and mutation discovery in tumors
(reviewed in [6-9]). The new data types they provide
are far cheaper than traditional capillary gel electrophor-
esis data, with the reduction in cost enabling projects
of unprecedented scale. However, current sequencing
technologies such as Illumina, 454, SOLiD and Ion
Torrent have systematic shortcomings that limit utility
of the data. Each of these has its own complex context-
specific error profile that results in false positive SNP
and indel calls. Short read lengths can result in mis-
mappings and misalignments [10,11] that make some
regions of the genome inaccessible. In addition, there* Correspondence: carneiro@broadinstitute.org
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reproduction in any medium, provided the orare representational biases, where regions of certain base
compositions (in particular very high or very low GC
composition) are underrepresented.
The Pacific Biosciences technology provides a funda-
mentally new data type that provides the potential to
overcome these limitations by providing significantly
longer reads (now averaging >1 kb), enabling more
unique seeds for reference alignment. In addition, the
lack of amplification in the library construction step
avoids a common source of base composition bias. With
these potential advantages in mind, we here evaluate the
utility of the Pacific Biosciences RS platform for human
medical amplicon resequencing projects by assessing the
quality of the raw sequencing data, as well as its use
for SNP discovery and genotyping using the Genome
Analysis Toolkit (GATK)[10].Results and discussion
We first defined the basic performance parameters of the
data, in terms of read length, base accuracy and error
profile, and sequence composition-based representationall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from human amplicons (see methods), we profiled read
length, showing an average of 700 bases over a wide dis-
tribution, including 5% of reads >2500 bases (Figure 1a).
Errors were characterized by comparison to the known
reference sequences (see methods), showing that the
primary error mode was insertions, at 12%, followed
by deletions, 2% and apparent mismatch errors at 1%
(Figure 1b). Further, errors were randomly distributed
across the read, rather than increasing in distal positions
as is true for other data types (Figure 1c). This property
by which read length and base position do not affect the
quality of the bases produced greatly facilitates alignment
of reads despite their relatively high indel rate. Finally,
since extreme base composition is a source of represen-
tational bias in many sequence data types, we evaluated
the performance of the Pacific Biosciences system using
a dataset (12 runs, 319,090 reads) derived from 3 micro-
bial genomes that span a much wider range of base
composition than the human genome (Plasmodium fal-
ciparum 19% GC, Escherichia coli 50% GC, Rhodobacter
sphaeroides 69% GC). The average relative coverage
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Figure 1 Characterization of Pacific Biosciences data. a) Base error mod
of reads in the Pacific Biosciences discovery dataset (here some raw reads
Shown are all errors (mismatch, insertion and deletion) by base position, in
(this is why the average is slightly higher than 15%). Due to the diminishin
positions up to 1000. d-f) GC bias of the Pacific Biosciences instrument rep
and R. sphaeroides (high GC) shows good balance in GC coverage where thto have little impact on data utility: between 53% and
110% of mean coverage for P. falciparum, between 79%
and 140% for E. coli, and between 64% and 120% for R.
sphaeroides (Figure 1d).
Base quality scores are a critical tool for accurate SNP
calling, and are used by most analysis algorithms to help
distinguish true variation from artifacts. Indeed, the
accuracy of the reported base quality scores has a signifi-
cant impact on the correctness of variation detection
[12]. We have found that Pacific Biosciences data under-
report true base qualities by on average 10 PHRED
scaled points. For this reason we applied a method to
generate empirical base quality scores for Pacific Bios-
ciences data using the base quality score recalibration
framework in the Genome Analysis Toolkit (GATK)[10].
Empirical quality scores generated with GATK are on
average Q20-Q24 for bases that are not insertions or
deletions. We observed no relationship between the
empirical quality scores and position in the read, similar
to accuracy of base calls.
Alignment is the process of mapping reads individually
to a region in the reference sequence where each read









e rate for deletions, insertions and mismatches. b) Length distribution
are as long as 5,000 bases). c) Pacific Biosciences error rate by position.
cluding every base sequenced despite any previously known variation
g number of reads with bases beyond 1000 we only plot here
resented by the genomes of P. falciparum (low GC), E. coli (average GC)
ere is sufficient data in the genome, regardless of GC content.
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base insertion and deletion rates, alignment of Pacific
Biosciences data challenges standard approaches. To
account for this, we set the gap open penalty to be lower
than the base mismatch penalty (see methods) in order
to maximize alignment performance. Despite aligning
most of the reads successfully, this creates the side effect
that the aligner will sometimes prefer to “hide” a true
SNP inside an insertion. The result is that mapping is
accurate, but the aligned sequence is biased toward the
reference at some indel positions (see Figure 2a and 2b),
although the “hidden” bases remain available for subse-
quent analysis. It is important to note however, that
reference bias is an artifact of the alignment process,
rather than of the data, and can be greatly reduced
by locally realigning the reads based on the reference
























Figure 2 Error profile of Pacific Biosciences data. a) A chart showing th
sites and how reference bias pulls the median significantly below the expe
the highest alignment score, allowing the aligner in some cases to hide th
score at the cost of reference bias. b) IGV browser (http://www.broadinstitu
of a case of aligner-created reference bias on Pacific Biosciences RS data. T
browser[18,19] screen snapshot of a region in the discovery dataset where
appear as a true heterozygous site whereas Pacific Biosciences RS data (wit
event in this region.realignment is not compatible with the length and the
high indel rate of Pacific Biosciences data, but we antici-
pate the development of new tools.
For all projects aimed at discovery of mutations or
variation, it is critical to follow-up with validation of the
variants called, either by sampling to determine the rate
at which calls are correct, or to confirm which exact
changes are real rather than art factual. Extension is an
approach similar to validation, but carried out as a dis-
covery process on samples that have not been sequenced
to determine the extent to which mutations are present
at the same base or in the same gene in a large number
of samples, rapidly and at relatively low cost. Today,
variants called by massively parallel sequencing are
commonly validated using either Sequenom genotyping,
Sanger sequencing or resequencing using an alternate





e number of observations of the alternate allele in all heterozygous
cted 0.5. This combination creates multiple possible alignments with
e true alternate allele inside an insertion to maximize the alignment
te.org/igv/) screenshot of the validation dataset showing an example
he true SNPs (C) are correctly called in individual reads. c) An IGV
Illumina HiSeq data suffers from context specific errors that makes it
h errors nearly random, though more frequent) clearly shows no
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for examples see[1,13-15]. Each of these options has
limitations. Sequenom genotyping can validate only the
specific mutation called, and so lacks the ability to iden-
tify base differences at sites that were not discovered (i.e.
unable to validate mutation load assays, gene burden
tests), and is thus much less effective for extension. Fur-
ther, accurate interpretation of Sequenom data requires
manual review, with the potential to introduce human
error. Sanger sequencing operates at low throughput
and also requires human interpretation of the sequen-
cing results, making it only suitable for small validation
assays. Using alternate sequencing platforms may not
provide the fast turnaround necessary (Illumina HiSeq)
for validation studies or may suffer from other context
specific error modes (SOLiD, 454) that often further
complicate the validation analysis. Sequencing with an
alternate technology is, nevertheless, the most statisti-
cally correct approach for validation, provided the
alternate sequencing methodology employs a different
approach from the original technology, with a different
spectrum of biases, error modes or other limitations.
We designed two targeted sequencing experiments to
evaluate the power of the Pacific Biosciences data type
as a tool for validation and extension and as a tool for
variant discovery. For both experiments we used the
GATK to discover sites (see methods for details on
site selection).
To evaluate Pacific Biosciences data for validation/
extension, we sequenced PCR-amplicons spanning 98
variant calls based on Illumina GA1 and GA2 data from
the 1000 G project. These had been previously validated
either as true de novo mutations (38 sites) or false call
artifacts (60 sites), using SOLiD, 454 and Sanger sequen-
cing chemistry[13]. Individual PCR amplicons spanning
the test set variants were generated, sequenced with
both the Pacific Biosciences RS and the Illumina MiSeq,
and the data were used to call SNPs. Performance of
data from the two platforms was similar by several
metrics. Pacific Biosciences data showed 97% sensitivity
and 98% specificity by correctly genotyping 96 of the 98
sites, with a negative predictive value of 98% and positive
predictive value of 97%. Illumina MiSeq data provided
100% sensitivity and 91% specificity, genotyping 93 out
of 98 sites correctly with 100% negative predictive value
and 88% positive predictive value (see Tables 1 and 2).
The miscalled sites from each data set were
then manually inspected. One site was wrongly called
monomorphic with the reference allele from Pacific
Biosciences data due to reference bias. The one site
wrongly called polymorphic from Pacific Biosciences
data was similarly miscalled in MiSeq and in our gold
standard HiSeq whole genome dataset (see methods).
From the 5 sites miscalled using data from IlluminaMiSeq, 2 were in agreement with Pacific Biosciences
(one listed above and one not called in Pacific Bios-
ciences due to reference bias), and 3 sites were called
polymorphic in error due to noise in the MiSeq data
(See Figure 2c for an example). Pacific Biosciences RS
data performed well by all metrics, and at a similar qual-
ity to Illumina data, demonstrating that the RS is a
powerful tool for follow up validation or extension.
To evaluate Pacific Biosciences data for variant discov-
ery, we sequenced 177 kb in 61 amplicons from regions
across human chromosome 20 using both Pacific Bios-
ciences RS and Illumina MiSeq. These amplicons con-
tained 225 SNPs that had been validated in our gold
standard deep whole genome call set (see methods),
which includes 43 previously validated as high-confidence
SNPs from Hap Map 3.3. A single Hap Map site was
called with very high confidence by amplicon-based data
from both technologies to have a different alternate allele
than Hap Map, and was similarly called with the whole
genome shotgun dataset. Thus, it likely reflects either a
single base change in our DNA sample source or an error
in Hap Map rather than a miscalled SNP. With Pacific
Biosciences data we called 197 of the 225 gold standard
sites (including 38 of the 43 Hap Map sites); with MiSeq
data we called 222/225 (and 43/43). We manually
inspected the sites of all the discordant calls, which fell
into two classes: 1) Reference bias, where the correct call
was obscured by reference bias in the alignment, and the
alternate allele was present in the data but hidden by the
alignment inside insertions; 2) Low sequence coverage,
where insufficient data were obtained to make a confident
call, likely due to poor PCR amplification of the target.
For the Pacific Biosciences data, the 28 sites missed from
the gold standard call set included 16 missing due
to reference bias and 12 due to lack of coverage. For
MiSeq data, the three sites missed were all due to low
sequence coverage.
Conclusions
Overall, this first look at Pacific Biosciences RS sequen-
cing data from human samples demonstrates that it is a
promising platform for follow-up validation and exten-
sion studies. We have shown that the data type is largely
free from context-specific error modes and is effective
both for site-specific validation and variation discovery.
Despite its current error rate, the stochastic nature of
the Pacific Biosciences error profile allows the standard
Bayesian variant calling algorithm used by the GATK to
make robust calls without any technology-specific modi-
fications. Though Pacific Biosciences data are more
expensive on a per base or per read basis than for
MiSeq, for the experiments described herein, reagent
costs are similar. We anticipate that future improve-
ments in yield in the Pacific Biosciences technology and
Table 1 Validation calls for Pacific Biosciences and Illumina MiSeq
Pacific Biosciences RS Pacific Biosciences RS Illumina MiSeq Illumina MiSeq
called Poly called Mono called Poly called Mono
Confirmed 37 1 38 0
de novo SNP
Confirmed 1 59 5 55
artifact
Number of sites called polymorphic and monomorphic by Pacific Biosciences RS and Illumina MiSeq in the validation experiment. Datasets were sequenced from
the same amplicons and were downsampled to 70x average coverage for comparison. Pacific Biosciences shows good accuracy with consistently high
percentages in all metrics and making only 2 out 98 wrong calls, while MiSeq shows excellent sensitivity and negative predictive value but lower specificity and
positive predictive value and 5 out of 98 wrong calls, all of the same class.
Poly = polymorphic site; Mono = monomorphic site.
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some of the remaining analytic challenges we found
using Pacific Biosciences data which will further increase
its utility in the field of human DNA sequencing.
Methods
Sample preparation
In this study we generated two datasets from the same
individual (NA12878) from the 1000 G project, one for
SNP validation and one for SNP discovery. For the valid-
ation dataset we sequenced 2,000 bp PCR amplicons
containing 120 de novo mutation calls that had been
identified using data from Illumina, SOLiD, and 454
sequencing technologies and subjected calls to follow-up
validation. 48 sites were confirmed as true de novo
mutations and 72 confirmed as false calls that in some
cases required more than one round of validation. For
the discovery dataset we sequenced 1,500 bp amplicons
covering 61 regions of chromosome 20. The same ampli-
cons were sequenced using Pacific Biosciences RS and
Illumina MiSeq and down sampled to an average 70x
coverage for direct comparison.
Sequence data processing
We used the Pacific Biosciences SMART analysis soft-
ware 1.2 to generate ‘filtered sub-reads’ from the instru-
ment. The term ‘sub-read’ refers to the portion of a read
from a single pass of the template. Filtering refers to
a process within the software to identify quality reads.
Filtered sub-reads are generated following primary
analysis where the SMART bell adaptors are separated
from the long raw reads, and low quality bases reported
by the instrument are removed, yielding sub-reads
700 bases long on average. In the text we simply call
sub-reads ‘reads’ to avoid confusion, and never refer toTable 2 Validation metrics for Pacific Biosciences and
Illumina MiSeq
Sensitivity Specificity PPV NPV
Pacific Bioscinces RS 97% 98% 97% 98%
Illumina MiSeq 100% 91% 88% 100%
PPV = positive predictive value; NPV = negative predictive value.raw reads. We did not use the secondary analysis pro-
vided by the Pacific Biosciences SMART analysis soft-
ware. Instead we used a BWA + GATK based pipeline
to create analysis-ready BAM files from the original
FAST file.
The pipeline starts with BWA-SW[16] read alignment
using non standard parameters (−b5 -q2 -r1 -z20). These
parameters were chosen after evaluating several other
options for the best yield (number of reads), coverage
of the targeted region, average read length and SNP-
calling sensitivity (compared to standard calls made with
Broad’s internal 60x coverage NA12878 HiSeq data).
Read group information is then added to the SAM file
and a BAM file is generated, sorted by coordinate order
using Picard’s tools AddOrReplaceReadGroups and Sorts
am respectively (picard.sourceforge.net). All datasets




Quality scores for the bases were generated by using the
GATK’s base quality score recalibration pipeline[10],
starting with a default original base quality of Q20 for
every base in the read. Base quality score recalibration
distributes the quality score according to the empirical
quality score of each base. The empirical quality score is
the likelihood that the base is correctly called based on
four covariates: Cycle, Di-nucleotide, Base Quality and
Read Group. The cycle covariate corrects the qualities
based on the position of the base in the read. The Di-
nucleotide covariate looks for systematic errors caused
by a specific previous base call, for example, if calling a
G usually makes the instrument more likely to call a
subsequent C even if that is incorrect. The base quality
covariate corrects for systematic variation in the quality
of bases and the read group covariate rectifies inconsist-
encies in qualities between different sequencing runs.
We tested this using the Pacific Biosciences SMART
software (version 1.2) secondary analysis quality scores
as original qualities for base quality score recalibration
but observed no improvement in the final empirical
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Pacific Biosciences does not provide a simple measure of
base quality score. Instead the software uses the instru-
ment’s estimated insertion error probability as the base’s
quality score. We found that this value was often 5–10
PHRED-scaled points below the empirical quality score.
We did not use the Pacific Biosciences reported base
quality scores because their systematic underestima-
tion of base qualities makes them less effective for vari-
ation detection.
Variant calling
SNP calling was performed using the GATK’s Unified Gen-
otyper with two added parameters to deal with the error
mode and error rate of Pacific Biosciences reads. Since
insertions and deletions are the primary error mode of
Pacific Biosciences, we allowed sites to have up to 50%
deletions with the parameter -deletions 0.8 and because the
average quality scores for bases present ranged from 20–24
we allowed the minimum base quality score to be Q10
(PHRED-scaled) with the parameter -mbq 10. Due to the
high coverage and small size of the datasets we did not ob-
serve any improvements in the calls by using hard (GATK’s
Variant Filtration) or soft (GATK’s Variant Quality Score
Recalibration pipeline) filters.
Validation was performed using GATK’s ‘Genotype
And Validate’ tool using the Pacific Biosciences BAM
files as input and a VCF file with the true call status of
the variants in the region. We generated this VCF file
using the GATK’s Variant Annotator and information
from the previous validation experiments with Illumina,
SOLiD and 454 data as part of the 1000 G project.
Genotype And Validate makes calls using the GATK’s
Unified Genotyper engine on every site in the validation
VCF given the alternate allele in the VCF file and calcu-
lates the likelihood of calling this alternate allele using
the Pacific Biosciences BAM file as input. The result is
then compared with the true status of the alternate allele
(true de novo or sequencing artifact). For each true
de novo called with Pacific Biosciences data the tool out-
puts a true positive, for each sequencing artifact not
called with Pacific Biosciences data the tool outputs a true
negative. False positives are sequencing artifacts called
with Pacific Biosciences and false negatives are true
de novo events not called with Pacific Biosciences data.
Discovery was performed using the GATK’s Unified
Genotyper directly with the parameters described above
and Variant Eval to analyze the metrics of the call set
(TiTv ratios, novel mutations, known mutations and
other metrics). We used NA12878 genotypes in Hap
Map 3.3 and our gold standard call set as our known
datasets. The datasets, the GATK and all tools used in
this work are freely available at http://www.broadinstitute.
org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit.Gold standard call set
The gold standard call set provided a highly reliable set
of known control variants. It was produced from whole
genome data sequenced to 60x from NA12878, and pro-
cessed using the current best practices for variant calling
as defined by the Broad Institute. The dataset was
aligned using BWA 0.5.9-r16 and the 1000 G project
b37 human reference. We realigned the reads using the
GATK’s Target Creator and Indel Realigner, marked
duplicate reads using Picard’s Mark Duplicates tool
and recalibrated quality scores using the GATK’s Base
Quality Score Recalibration pipeline consisting of the
Count Covariates tool and the Table Recalibration tool.
Calls were made using the GATK’s Unified Genotyper
and filtered using the GATK’s Variant Quality Score
Recalibration tool. The sequence data set and gold stand-
ard call set are available at http://www.broadinstitute.
org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit.
Lab methods
PCR amplicons were generated as follows. PCR reactions
were performed in a volume of 30 ul containing 30 ng
DNA (NA12878, Coriell), 0.05 U PfuUltra II Fusion HS
DNA polymerase (Agilent), 1x PfuUltra II Fusion buffer
(Agilent), 0.4 uM primers (Integrated DNA Technolo-
gies), 0.66 mM dNTP (Agilent), 1% DMSO (VWR)
and 1.15 M Betaine (Sigma-Aldrich). Using a thermal
cycler (Master cycler ep gradient, Eppendorf ) PCR was
performed using 1 cycle of 95°C for 3 min, 40 cycles of
94°C for 30 sec, 55°C for 30 sec, and 72°C for 2 min fol-
lowed by 1 cycle of 72°C for 10 min. PCR amplicons
were quantified using a Quant-iT DNA Assay Kit, High
Sensitivity (Invitrogen), normalized to the same con-
centration and 100 ng of each PCR product was com-
bined into a pool. Pacific Biosciences sequencing
libraries were generated from pooled PCR amplicons
and sequenced on Pacific Biosciences RS following man-
ufacturer’s recommendations. The 2000 bp amplicons
were sheared to ~250 bp in size prior to library con-
struction following manufacturer’s recommendations
(Pacific Biosciences). The 1,500 bp amplicons were
processed without shearing. Illumina paired-end frag-
ment libraries were generated and sequenced on MiSeq
following manufacturer’s recommendations (Illumina).
Both 1,500 bp and 2,000 bp amplicons were sheared
to ~200 bp in size following manufacturer’s recom-
mendations (Illumina). For each amplicon pool library
construction and sequencing were carried out independ-
ently. Data for E. coli, R. sphaeroides and P. falciparum
was generated on a previous study [17] where the lab
methods are thoroughly described.
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